ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23^rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

23^rd Annual Needham Virtual Healthcare Conference

The webcast will also be available under "Event Calendar" on I-Mab's IR website
at http://ir.i-mabbiopharma.com/

For more information, please contact your Needham representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.